Joshua Wang, is currently the Founder and CEO of VerImmune inc. As CEO, he has raised over $15M in financing for VerImmune of which 1/3 has been from non-dilutive or pharma licensing revenue. He was trained at Johns Hopkins (vaccine immunology/vaccine platforms) and has experience in the biotech industry. Before starting VerImmune, Joshua was involved in the development of another vaccine start-up as an operational founder and worked at Flagship Ventures as a fellow, where he was part of the initial exploration that led to the discovery of the AnelloVector platform and creation of Ring Therapeutics